Full Press Release Details
61 2 9878 0088 (Australia)
Monday February 8, 2010
Marshall Edwards, Inc. announces resignation of Christopher Naughton from Board of Directors
Sydney, Australia February 8, 2010 Marshall Edwards, Inc. (NASDAQ: MSHL) announced that
Christopher Naughton had resigned as a member of the Board of Directors effective February 5, 2010.
The Board of Directors intends to fill the vacancy created by Mr. Naughton s resignation. As a
result of Mr. Naughton s resignation, the size of the Board of Directors has decreased from five to
About Marshall Edwards
Marshall Edwards, Inc. (NASDAQ: MSHL) is a specialist oncology company focused on the clinical
development of novel anti-cancer therapeutics. These derive from a flavonoid technology platform,
which has generated a number of novel compounds characterized by broad ranging activity against a
range of cancer cell types with few side effects. The combination of anti-tumor cell activity and
low toxicity is believed to be a result of the ability of these compounds to target an enzyme
present in the cell membrane of cancer cells, thereby inhibiting the production of pro-survival
proteins within the cell. Marshall Edwards, Inc. has licensed rights from Novogen Limited (ASX NRT
NASDAQ: NVGN) to bring four oncology drugs phenoxodiol, triphendiol, NV-143 and NV-128 to
Marshall Edwards, Inc. is majority owned by Novogen, an Australian biotechnology company that is
specializing in the development of therapeutics based on a flavonoid technology platform. More
information on phenoxodiol and on the Novogen group of companies can be found at
Forward Looking Statements
Under U.S. law, a new drug cannot be marketed until it has been investigated in clinical trials
and approved by the U.S. Food and Drug Administration (the FDA ) as being safe and effective for
the intended use. Statements included in this press release that are not historical in nature are
forward-looking statements within the meaning of the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. You should be aware that our actual results could differ
materially from those contained in the forward-looking statements, which are based on management s
current expectations and are subject to a number of risks and uncertainties, including, but not
limited to, our failure to successfully commercialize our product candidates; costs and delays in
the development and/or FDA approval, or the failure to obtain such approval, of our product
candidates; uncertainties in clinical trial results; our inability to maintain or enter into, and
the risks resulting from our dependence upon, collaboration or contractual arrangements necessary
for the development, manufacture, commercialization, marketing, sales and distribution of any
products; competitive factors; our inability to protect our patents or proprietary rights and
obtain necessary rights to third party patents and intellectual property to operate our business;
our inability to operate our business without infringing the patents and proprietary rights of
others; general economic conditions; the failure of any products to gain market acceptance; our
inability to obtain any additional required financing; technological changes; government
regulation; changes in industry practice; and one-time events. We do not intend to update any of
these factors or to publicly announce the results of any revisions to these forward-looking